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Abstract 
The present study was designed for the development of a stable sustained 
release liposomal drug delivery system for tamoxifen citrate (TC) using soya 
phosphatidylcholine (SPC), cholesterol (CH) and span 20 as main ingredients. 
Liposomes were prepared by formation of thin lipid film followed by hydration. 
The mean vesicle diameter was found to be 203.5 ± 19.5 nm with 21% of the 
liposomal population having average diameter below 76.72 ± 6.7 nm. There 
was a good vesicular distribution with the polydispersity index of 0.442 ± 0.03. 
The maximum loading of drug was determined to be 53.60% of the initial 
amount that is 34.58 µg of drug per mg of lipid. Amongst the different storage 
conditions, liposomes stored at 2–8°C were found to be most stable and only 
4% of the drug was lost over the storage period of 5 weeks. In vitro release 
studies of liposomes showed that 50% of drug was released within 3 hours (h) 
whereas 95% drug was released in 30 h. This indicates the usefulness of the 
liposomal delivery system for sustaining the in vitro release of tamoxifen citrate. 
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Introduction 
Tamoxifen citrate, an anti-estrogen compound, is the first choice hormonal treatment of 
breast cancer in both pre- and post-menopausal women for last few decades. It is often 
used as an adjuvant therapy following primary treatment of early stage breast cancer   
[1–3]. Depending upon the dose and tissue, tamoxifen can act either as an anti-estrogenic 
or as an estrogen. To the breast, it is an anti-estrogenic, however it also has estrogenic 
effects on uterus and one of the significant side effects of postmenopausal tamoxifen 
treatment appears to be endometrial carcinoma [4]. Other side effects include liver cancer, 
venous thrombosis, pulmonary emboli and ocular effects such as retinopathy and corneal 
opacities [5]. These side effects were reported to be dose and concentration dependent 
[6]. Therefore the aim of tamoxifen therapy for long term chemoprevention of breast 
cancer is to deliver a lower dose of drug over a prolong period of time.  
In the present investigation, our main objective was to develop a simple vesicular delivery 
system for tamoxifen citrate which can deliver drug at a lower concentration over a prolong 
period of time and thereby reducing the potential dose related side effects. 
Results and Discussion 
To determine the drug-excipient interactions FTIR studies were conducted before 
development of the formulations. Drug-excipient interaction study is one of the most 
important parameters, which depicts much information regarding the stability of 
formulations, drug release from them and drug availability patterns [7]. 
 
Fig.1.   FTIR spectrums: (A) Pure drug TC; (B) Physical mixture of excipients; (C) 
Physical mixture of drug and excipients 
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Fig. 1C shows the minor shifting of some peaks compared to pure drug (Fig. 1A) and 
physical mixture of excipients (Fig. 1B), like aliphatic alcoholic O-H stretch (3405.50–
3395.04 cm
−1), phenolic C-O stretch (1362.48–1371.81 cm
−1), and C-O stretch of ether 
(1048.39–1061.57 cm
−1). These shifts may be because of formation of hydrogen bonds, or 
some other weak forces like van der Wall forces or dipole moment amongst the polar 
functional groups of drug and phospholipids moieties. However, these interactions may 
favor the formation of vesicular shape, stability of structure and slower drug release [8]. 
In order to determine the influence of formulation components on the percent drug loading 
(PDL), composition with varying ratios of drug, SPC and CH were studied (data show 
mean ± S.D. and n = 3) (Table 1). For CH free SPC liposomes (TCL 1-TCL 4), maximum 
drug loading of 43.83% could be achieved at a drug-lipid ratio of 1:10 (w/w). The drug 
entrapment value can be further increased by 4-28% with the addition of 10 to 60% (w/w) 
of CH (TCL 5-TCL 10, Table 1). Results showed that incorporation of CH enhanced the 
percent of drug entrapment up to 55% (w/w) but further increase in CH decreases this 
value. The addition of CH has been shown to lend greater stability to the bilayer 
membranes by raising the gel liquid transition temperature of the vesicles. This stability 
decreases leakage of the vesicle and stabilizes it against osmotic gradient and thereby 
increasing the drug loading [9]. The further increase in the amount of CH reduces the drug 
entrapment because CH itself is incapable to form vesicles and also hinder the entry of 
drug molecule by occupying the space in phospholipid bilayer. 
















(µg of drug : 
mg of lipid)
a 
TCL 1  5:100:0  1.99±0.13  39.80  19.9:1 
TCL 2  7.5:100:0  3.17±0.14  42.26  31.7:1 
TCL 3  10:100:0  4.38±0.23  43.83  43.83:1 
TCL 4  12.5:100:0  4.33±0.13  34.64  43.30:1 
TCL 5  10:100:10  4.57±0.19  45.68  41.52:1 
TCL 6  10:100:20  4.76±0.16  47.60  39.66:1 
TCL 7  10:100:40  5.02±0.20  50.21  35.86:1 
TCL 8  10:100:50  5.20±0.16  51.97  34.65:1 
TCL 9  10:100:55  5.36±0.18  53.60  34.58:1 
TCL 10  10:100:60  5.07±0.17 50.72  31.70:1 
TCL…tamoxifen citrate liposomes; TC…tamoxifen citrate, SPC…soya phosphatidylcholine, 
CH…cholesterol; 
a ratio was determined based on the initial amount of lipid used 
The size range of TCL 9 blank liposomes (without drug) was found to be within 50 to 800 
nm with 46.86% of the liposomal population having average diameter of 153.2 ± 10.2 nm. 
The mean vesicle diameter was found to be 205 ± 15.2 nm (Table 2). The size range of 
TCL 9 drug loaded liposomes (Fig. 2) was found to be 38 to 700 nm, with 21.01% of the 
liposomal population having average size of 76.72 ± 6.7 nm. The mean vesicle diameter 
was found to be 203.5 ± 19.5 nm (Table 2). 
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(nm) (n = 3) 
Polydispersity 
index (n = 3) 
Zeta potential 
(mV) (n = 3) 
TCL 9blank  25  205.0 ± 15.2  0.351 ± 0.02  −56.09 ± 4.3 
TCL 9drug  25  203.5 ± 19.5  0.442 ± 0.03  −36.88 ± 3.8 
 
Results showed that there was no significant difference between the size of blank and 
drug loaded liposomes. This may be attributed to the fact that TC is encapsulated in the 
lipid membrane [10]. The reproducibility of the liposomal formulation with respect to size 
was confirmed by preparing the formulation three times. 
When zeta potential was studied to understand the surface charges of the vesicles it was 
noticed that zeta potential of the formulation without drug was strongly negative, whereas 
those with drug became less negative (Table 2). This is due to the cationic charge present 
on the drug having neutralized the surface charges existed on the formulation surface [11]. 
Although, the zeta potential of drug loaded liposomes decreased but still was sufficient to 
prevent the fusion of vesicles as the colloids with high zeta potentials (positive or negative) 
are electrically stabilized, while colloids with low zeta potentials tend to coagulate or 
flocculate.  
 
Fig. 2.   SEM photograph of drug loaded liposomes (TCL 9) 
The storage stability of TCL 9 liposomes were investigated in terms of aggregation, fusion 
and vesicle disruption tendencies. The bar diagram (data show mean ± S.D. and n = 3) 
(Fig. 3) shows the leakage of drug from liposomes at different storage conditions over the 
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period of 5 weeks. Furthermore, it was found that approximately 13–15.5% of drug was 
lost at elevated temperatures of 37 ± 2°C and 45 ± 2°C, respectively. On the other hand 
almost 93.8 and 96% of drug remained incorporated at room temperature (RT) and 
refrigeration temperature (RF), respectively which are in accordance with the reported 
results [12]. TCL 9 liposomes exhibited excellent stability in terms of aggregation, fusion 
and vesicle disruption. This high stability of liposomes may be due to the cementing effect 
of cholesterol and thereby preventing the leakage of drug from vesicles during storage. 
The leakage of drug from the vesicles stored at elevated temperature might be due to the 
effect of high temperature on the gel to liquid transition of lipid bilayers together with 
possible chemical degradation of the phospholipid component [12]. Therefore this study 
suggests the storage of liposomal formulation in refrigerator in order to prevent loss of 
drug from the liposomes.  
 
Fig. 3.   Extent of drug leakage from liposomes (TCL 9) at different storage conditions. 
Data shows mean ± S.D. (n=3) 
During in vitro release studies of tamoxifen from the liposomes, it was found that about 
50% (Fig. 4) of drug was released within 3 h and about 95% of drug was released after 
30 h. This extended release could be attributed to the decreased membrane fluidity of 
phospholipid bilayer by cholesterol and tamoxifen itself [13] and thereby preventing the 
burst release [14] as well as decrease the rate of drug released from vesicles. Therefore, 
the optimized formulation was able to release the drug over a prolonged period of time to 
reduce the dose related toxic effects. 
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Fig. 4.   In vitro release of TC from the liposomes (TCL 9) using PBS buffer (pH 7.4) at 
37°C. Data shows mean ± S.D. (n=3) 
Experimental 
Materials 
Tamoxifen citrate (TC) was a kind gift from Biochem Pharmaceutical Industries, India. 
Soya phosphatidylcholine (SPC) was purchased from HiMedia Laboratories Pvt. Ltd, 
Mumbai, India. Cholesterol (CH) was procured from E. Merck (India) Ltd., Mumbai, India. 
All other ingredients used in the study were of analytical grade.  
Methods 
Liposomes were prepared by thin film hydration method. The weighed amounts of TC, 
SPC, CH, span 20 and BHT (2 % w/w of total lipid) (Table 1) were dissolved in chloroform-
methanol mixture (2:1, v/v). The mixture was placed in a rotary vacuum evaporator with an 
aspirator and was rotated at 120 rpm. The temperature of the water bath was maintained 
at 35-40°C to evaporate the solvent. Subsequently, the flask was kept in a vacuum 
desiccator overnight for complete removal of residual solvent. The dried lipid film was 
hydrated with phosphate buffer solution (PBS, pH 7.4) in a rotary vacuum evaporator 
maintained at 60°C and rotated at 120 rpm until the lipid film was dispersed in the aqueous 
phase. The size reduction of vesicles was done by a bath-sonicator (30 ± 2 KHz) at 60°C 
for 1  h. Then the dispersion was left undisturbed at room temperature for 1–2  h for 
complete vesicle formation followed by storage at 4°C in an inert atmosphere for 24 h. 
Next day the preparation was centrifuged at 5000 rpm at 4°C for 5 min. The supernatant 
containing the vesicles in each case was taken for further studies. 
Fourier transform, infrared (FTIR) study 
The pure drug TC, physical mixture of SPC, CH and BHT, and physical mixture of TC, 
SPC, CH and BHT were mixed separately with infrared (IR) grade KBr in the ratio of 1:100 
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and corresponding pellets were prepared by applying 15000 lb of pressure in a hydraulic 
press. The pellets were scanned in an inert atmosphere over a wave number range of 
4000-400 cm
–1 in Magna IR 750 series II (Nicolet, USA) FTIR instrument. 
Size distribution and zeta potential  
Different batches of liposomes were monitored for their morphological attributes with the 
help of scanning electron microscope (SEM) (JSM, JEOL, Tokyo, Japan). Fusion and 
crystallization were detected by optical microscopy. Size distribution and Zeta potential of 
liposomes were measured by dynamic light scattering method using Zetasizer nano ZS 
(Malvern Instruments Ltd., UK) in triplicate. 
Drug loading study 
Freshly prepared liposomal suspensions (with or without drug) were ultracentrifuged at 
120000 x g at 25°C for 1 hr (Sorvall, USA) with fix rotor type s 20/20 (DuPont, USA) to 
pelletize liposomes [15]. The pellet was then lyophilized and resulting powder containing 
liposomes was dissolved in ethanol to obtain a clear solution and absorbance was 
measured at 274 nm using UV/VIS spectrophotometer (Beckman, USA). Liposomes 
prepared without drug were treated in similar way and used as blank for the above study. 
The drug content was then determined from the standard curve. The percent drug loading 
for the prepared liposomes was calculated as in Eq. 1.  
Eq. 1.  100
(mg)   added   drug   Total
(mg)   drug   Entrapped
  loading   Drug   % ⋅ =  
Storage stability studies 
The drug retentive capacity of the vesicles was studied by keeping the liposomal 
dispersion at four different temperatures i.e., 2–8°C (RF), 25 ± 2°C (RT), 37 ± 2°C and 45 
± 2°C for a period of 5 weeks [16] in sealed ampoules after flushing with nitrogen. The 
drug content of vesicles was determined periodically. 
In vitro drug release 
In vitro release of TC from liposomes was conducted by dialysis in a dialysis sac (Sigma, 
12000 MW cut off) with 200 ml of PBS (pH 7.4) at 37°C [17]. Briefly, in a 250 ml conical 
flask, 200 ml of PBS was taken. One ml of formulation was taken into a dialysis bag and 
dipped into the buffer solution. The flask was kept on a magnetic stirrer. Stirring was 
maintained at 250 rpm and the temperature of the buffer was maintained at 37°C. 
Sampling was done by withdrawing 0.5 mL from the released medium with the help of 
micropipette and 0.5 mL of fresh buffer was added. Samples were analyzed using a 
spectrophotometer at a wave length of 274 nm. With the help of the standard curve 
prepared earlier, drug concentration was measured. 
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